INCYTE CORPORATION Gain (Loss) Related to Litigation Settlement
INCYTE CORPORATION (INCY) reported Gain (Loss) Related to Litigation Settlement of $242.25 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossRelatedToLitigationSettlement · last filed 2026-02-10
- INCYTE CORPORATION gain (loss) related to litigation settlement for the quarter ending 2025-12-31 was $0.00.
- INCYTE CORPORATION gain (loss) related to litigation settlement for the quarter ending 2025-09-30 was $0.00.
- INCYTE CORPORATION gain (loss) related to litigation settlement for the quarter ending 2025-06-30 was $242.25M.
- INCYTE CORPORATION gain (loss) related to litigation settlement for the quarter ending 2025-03-31 was $0.00.
- INCYTE CORPORATION gain (loss) related to litigation settlement for fiscal 2025 was $242.25M.
- INCYTE CORPORATION gain (loss) related to litigation settlement for fiscal 2024 was $0.00.
- INCYTE CORPORATION gain (loss) related to litigation settlement for fiscal 2023 was $0.00.
| Period end | Gain (Loss) Related to Litigation Settlement 3 month | Gain (Loss) Related to Litigation Settlement 6 month | Gain (Loss) Related to Litigation Settlement 9 month | Gain (Loss) Related to Litigation Settlement 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $0.00 derived: sum of 2 quarters · filed 2026-02-10 | $242.25M derived: sum of 3 quarters · filed 2026-02-10 | $242.25M 10-K · filed 2026-02-10 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-28 | $242.25M derived: sum of 2 quarters · filed 2025-10-28 | $242.25M 10-Q · filed 2025-10-28 | $242.25M derived: sum of 4 quarters · filed 2026-02-10 |
| 2025-06-30 | $242.25M 10-Q · filed 2025-07-29 | $242.25M 10-Q · filed 2025-07-29 | $242.25M derived: sum of 3 quarters · filed 2026-02-10 | $242.25M derived: sum of 4 quarters · filed 2026-02-10 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-02-10 | $0.00 derived: sum of 2 quarters · filed 2026-02-10 | $0.00 derived: sum of 3 quarters · filed 2026-02-10 | $0.00 derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $0.00 derived: sum of 2 quarters · filed 2026-02-10 | $0.00 derived: sum of 3 quarters · filed 2026-02-10 | $0.00 10-K · filed 2026-02-10 |
| 2024-09-30 | $0.00 10-Q · filed 2025-10-28 | $0.00 derived: sum of 2 quarters · filed 2025-10-28 | $0.00 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-07-29 | $0.00 10-Q · filed 2025-07-29 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |